#United States #New York #Securities Class #Park Ha Bio #BYAH Stock

Park Ha Biological Technology Co., Ltd. Faces Rising Controversy Over Stock Collapse

In a significant turn of events, Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) is currently at the center of a securities class action lawsuit following a shocking 93% drop in its stock price on July 8, 2025. The decline wiped out more than $1 billion of market capitalization in a single trading session, raising serious questions regarding the company’s operational integrity and financial reporting.

Background of the Case

The lawsuit primarily targets shareholders who acquired BYAH securities between December 27, 2024 and July 8, 2025. Investors are being urged to come forward as they may be eligible to recover some of their losses. On the day of the stock's dramatic decline, shares plunged by $38.02, closing at a mere $2.99 after trading of more than 8.9 million shares.

As the franchise model of BYAH comes under scrutiny, it’s revealed that the company had reported only 39 franchisees and a meager franchise fee revenue of $551,970 for the first six months of 2025. This led to allegations that there was a disconnection between its reported operational performance and the market capitalization it enjoyed, which had briefly surpassed $1 billion at its peak.

Key Allegations in the Class Action

The case sheds light on several troubling aspects of BYAH’s operational health:

• - The IPO price was set at $4.00, generating around $4.8 million in revenues, with an implied valuation of approximately $96 million.
• - The company's reported gross profit margins of 93% on non-franchise products have been called into question, leading many to wonder about the sustainability of these figures in light of recent financial disclosures.

The lawsuit suggests that before the collapse, there were no significant corporate developments or operational milestones reported that would justify the run-up in share price. A glaring omission from the company was its failure to publicly address the unusual trading that occurred on the collapse day, creating further alarm amongst investors.

Expert Insights

Joseph E. Levi, an attorney representing a portion of the investors, emphasized that the allegations warrant serious consideration, pointing out that the discrepancy between the company's reported performance and its market value raises fundamental questions about investor information accuracy. “The case highlights whether investors truly received accurate and complete information about a business with limited operational reach that once was valued at over $1 billion,” he commented.

Timeline for Investors

Claimants have until September 28, 2026, to apply for lead plaintiff status in the class action. Interested investors are encouraged to gather brokerage records detailing their purchase dates, shares bought, and amounts paid to bolster their claim within the investigation.

For investors wondering about potential recovery options, the class action is structured on a contingency basis, meaning that there are no upfront costs involved in participation. This framework allows those who have faced losses to seek counsel without financial burden.

Conclusion

As the Park Ha Biological Technology saga unfolds, it represents a cautionary tale about the volatility of securities and the importance of transparency in financial disclosures. Investors who feel aggrieved by their experience in the BYAH rollercoaster are advised to consult with legal experts to better understand their rights and options as this significant lawsuit progresses.

For inquiries or more information regarding the lawsuit, affected investors can reach out directly to Joseph E. Levi, Esq., at SueWallSt, or contact their offices directly.

Contact Information

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor,
New York, NY 10004
Email: [email protected]
Phone: (888) SueWallSt

This unfolding story continues to impact numerous stakeholders in the investment community, and further developments will be closely monitored in the coming weeks.